Abstract
Enantiomerically pure product synthesis plays a key role in production of pharmaceuticals. The application of biocatalytic approaches represents a convenient and sustainable way for this purpose. The enormous potential of enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enantioselectivity is on increasing awareness. In particular, lipases show a high versatility to recognize non-natural substrates being successfully applied in regio- and stereoselective biotransformations. The immobilization technology on lipases is not only a requisite for the industrial implementation but it has been a great methodology to alter their catalytic properties to obtain highly enantio- and regioselective biocatalysts in the enantioselective synthesis of chiral drugs or drug intermediates. This review focuses on showing some of the latest advances on the use of immobilized lipases on pharmaceutical biotransformations.
Keywords: Lipases, kinetic resolution, asymmetric transformation, chemical modification, immobilization, pharmaceuticals, carbohydrates.
Current Bioactive Compounds
Title:Synthesis of Enantiopure Drugs and Drug Intermediates by Immobilized Lipase-Catalysis
Volume: 9 Issue: 2
Author(s): Jana Brabcova, Marco Filice, Melissa Gutarra and Jose M. Palomo
Affiliation:
Keywords: Lipases, kinetic resolution, asymmetric transformation, chemical modification, immobilization, pharmaceuticals, carbohydrates.
Abstract: Enantiomerically pure product synthesis plays a key role in production of pharmaceuticals. The application of biocatalytic approaches represents a convenient and sustainable way for this purpose. The enormous potential of enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enantioselectivity is on increasing awareness. In particular, lipases show a high versatility to recognize non-natural substrates being successfully applied in regio- and stereoselective biotransformations. The immobilization technology on lipases is not only a requisite for the industrial implementation but it has been a great methodology to alter their catalytic properties to obtain highly enantio- and regioselective biocatalysts in the enantioselective synthesis of chiral drugs or drug intermediates. This review focuses on showing some of the latest advances on the use of immobilized lipases on pharmaceutical biotransformations.
Export Options
About this article
Cite this article as:
Brabcova Jana, Filice Marco, Gutarra Melissa and Palomo M. Jose, Synthesis of Enantiopure Drugs and Drug Intermediates by Immobilized Lipase-Catalysis, Current Bioactive Compounds 2013; 9(2) . https://dx.doi.org/10.2174/22115528112019990009
DOI https://dx.doi.org/10.2174/22115528112019990009 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery 3-Hydroxy-2-phenyl-4(1H)-quinolinones as Promising Biologically Active Compounds
Mini-Reviews in Medicinal Chemistry Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Pigment Epithelium-Derived Factor (PEDF) Augments Vascular Endothelial Growth Factor (VEGF)-Induced Recovery of Limb Perfusion after Ischemia in Klotho Mouse
Letters in Drug Design & Discovery Endoscopic Microscopy Using Optical Coherence Tomography
Current Medical Imaging Enhanced Efficacy of DNA Vaccines Against an Intracellular Bacterial Pathogen by Genetic Adjuvants
Current Pharmaceutical Biotechnology The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design The Bioreactor: A Powerful Tool for Large-Scale Culture of Animal Cells
Current Pharmaceutical Biotechnology Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Exosome as a Natural Gene Delivery Vector for Cancer Treatment
Current Cancer Drug Targets Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Enzyme Inhibition Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Management of Endometrial Cancer: A Review
Reviews on Recent Clinical Trials Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy